Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab plus etoposide/platinum vs etoposide/platinum in extensive-stage small cell lung cancer
jRCT2080222136Phase 3
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ipilimumab in small cell lung cancer (SCLC) (2 arms), sponsored by Bristol Myers Squibb.
02
Drugs
ipilimumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2080222136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222136.